Everolimus for subependymal giant cell astrocytoma: 5‐year final analysis

Publisher： John Wiley & Sons Inc

E-ISSN： 1531-8249|78|6|929-938

ISSN： 0364-5134

Source： ANNALS OF NEUROLOGY, Vol.78, Iss.6, 2015-12, pp. : 929-938

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Neonatal Subependymal Giant Cell Astrocytoma

By  

Pediatric Neurosurgery, Vol. 36, Iss. 5, 2002-05 ,pp. : 271-274

Karger

Access to resources Recommend Favorite

Thyroid transcription factor‐1 and epithelial membrane antigen expression in four cases of subependymal giant cell astrocytoma

By  

HISTOPATHOLOGY, Vol. 66, Iss. 7, 2015-06 ,pp. : 1035-1036

John Wiley & Sons Inc

Access to resources Recommend Favorite

Dose‐level response rates of mtor inhibition in tuberous sclerosis complex (TSC) related subependymal giant cell astrocytoma (SEGA)

By  

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 62, Iss. 10, 2015-10 ,pp. : 1754-1760

John Wiley & Sons Inc

Access to resources Recommend Favorite

Factors affecting response to everolimus therapy for subependymal giant cell astrocytomas associated with tuberous sclerosis

By  

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 62, Iss. 4, 2015-04 ,pp. : 616-621

John Wiley & Sons Inc

Access to resources Recommend Favorite

BRAF V600E mutations are frequent in dysembryoplastic neuroepithelial tumors and subependymal giant cell astrocytomas

By  

JOURNAL OF SURGICAL ONCOLOGY, Vol. 111, Iss. 3, 2015-03 ,pp. : 359-364

John Wiley & Sons Inc

Access to resources Recommend Favorite